PMID- 36070850
OWN - NLM
STAT- MEDLINE
DCOM- 20221216
LR  - 20221221
IS  - 1873-1597 (Electronic)
IS  - 1572-1000 (Linking)
VI  - 40
DP  - 2022 Dec
TI  - Prediction of the response to photodynamic therapy in patients with chronic 
      central serous chorioretinopathy based on optical coherence tomography using deep 
      learning.
PG  - 103107
LID - S1572-1000(22)00393-3 [pii]
LID - 10.1016/j.pdpdt.2022.103107 [doi]
AB  - PURPOSE: To assess the prediction of the response to photodynamic therapy (PDT) 
      in chronic central serous chorioretinopathy (CSCR) based on spectral-domain 
      optical coherence tomography (SD-OCT) images using deep learning (DL). METHODS: 
      Retrospective study including 216 eyes of 175 patients with CSCR and persistent 
      subretinal fluid (SRF) who underwent half-fluence PDT. SD-OCT macular examination 
      was performed before (baseline) and 3 months after treatment. Patients were 
      classified into groups by experts based on the response to PDT: Group 1, complete 
      SRF resorption (n = 100); Group 2, partial SRF resorption (n = 66); and Group 3, 
      absence of any SRF resorption (n = 50). This work proposes different 
      computational approaches: 1st approach compares all groups; 2nd compares groups 
      1 vs. 2 and 3 together; 3rd compares groups 2 vs. 3. RESULTS: The mean age was 
      55.6 +/- 10.9 years and 70.3% were males. In the first approach, the algorithm 
      showed a precision of up to 57% to detect the response to treatment in group 1 
      based on the initial scan, with a mean average accuracy of 0.529 +/- 0.035. In the 
      second model, the mean accuracy was higher (0.670 +/- 0.046). In the third 
      approach, the algorithm showed a precision of 0.74 +/- 0.12 to detect the response 
      to treatment in group 2 (partial SRF resolution) and 0.69 +/- 0.15 in group 3 
      (absence of SRF resolution). CONCLUSION: Despite the high clinical variability in 
      the response of chronic CSCR to PDT, this DL algorithm offers an objective and 
      promising tool to predict the response to PDT treatment in clinical practice.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Fernandez-Vigo, Jose Ignacio
AU  - Fernandez-Vigo JI
AD  - Retina Unit, Ophthalmology Department, Hospital Clinico San Carlos, Madrid, 
      Spain. Electronic address: jfvigo@hotmail.com.
FAU - Gomez Calleja, Veronica
AU  - Gomez Calleja V
AD  - Retina Unit, Ophthalmology Department, Hospital Clinico San Carlos, Madrid, 
      Spain.
FAU - de Moura Ramos, Jose Joaquim
AU  - de Moura Ramos JJ
AD  - VARPA Research Group, Instituto de Investigacion Biomedica de A Coruna (INIBIC), 
      CITIC, Universidad da Coruna, A Coruna, Spain.
FAU - Novo-Bujan, Jorge
AU  - Novo-Bujan J
AD  - VARPA Research Group, Instituto de Investigacion Biomedica de A Coruna (INIBIC), 
      CITIC, Universidad da Coruna, A Coruna, Spain.
FAU - Burgos-Blasco, Barbara
AU  - Burgos-Blasco B
AD  - Retina Unit, Ophthalmology Department, Hospital Clinico San Carlos, Madrid, 
      Spain.
FAU - Lopez-Guajardo, Lorenzo
AU  - Lopez-Guajardo L
AD  - Retina Unit, Ophthalmology Department, Hospital Clinico San Carlos, Madrid, 
      Spain.
FAU - Donate-Lopez, Juan
AU  - Donate-Lopez J
AD  - Retina Unit, Ophthalmology Department, Hospital Clinico San Carlos, Madrid, 
      Spain.
FAU - Ortega-Hortas, Marcos
AU  - Ortega-Hortas M
AD  - VARPA Research Group, Instituto de Investigacion Biomedica de A Coruna (INIBIC), 
      CITIC, Universidad da Coruna, A Coruna, Spain.
LA  - eng
PT  - Journal Article
DEP - 20220905
PL  - Netherlands
TA  - Photodiagnosis Photodyn Ther
JT  - Photodiagnosis and photodynamic therapy
JID - 101226123
RN  - 0X9PA28K43 (Verteporfin)
RN  - 0 (Photosensitizing Agents)
RN  - 0 (Porphyrins)
SB  - IM
MH  - Male
MH  - Humans
MH  - Adult
MH  - Middle Aged
MH  - Aged
MH  - Female
MH  - *Central Serous Chorioretinopathy/diagnostic imaging/drug therapy
MH  - *Photochemotherapy/methods
MH  - Tomography, Optical Coherence/methods
MH  - Verteporfin/therapeutic use
MH  - Retrospective Studies
MH  - *Deep Learning
MH  - Fluorescein Angiography/methods
MH  - Photosensitizing Agents/therapeutic use
MH  - *Porphyrins/therapeutic use
MH  - Visual Acuity
MH  - Chronic Disease
OTO - NOTNLM
OT  - Central serous chorioretinopathy
OT  - Deep learning
OT  - Optical coherence tomography
OT  - Photodynamic therapy
COIS- Declaration of Competing Interest None.
EDAT- 2022/09/08 06:00
MHDA- 2022/12/15 06:00
CRDT- 2022/09/07 19:24
PHST- 2022/07/03 00:00 [received]
PHST- 2022/08/30 00:00 [revised]
PHST- 2022/09/02 00:00 [accepted]
PHST- 2022/09/08 06:00 [pubmed]
PHST- 2022/12/15 06:00 [medline]
PHST- 2022/09/07 19:24 [entrez]
AID - S1572-1000(22)00393-3 [pii]
AID - 10.1016/j.pdpdt.2022.103107 [doi]
PST - ppublish
SO  - Photodiagnosis Photodyn Ther. 2022 Dec;40:103107. doi: 
      10.1016/j.pdpdt.2022.103107. Epub 2022 Sep 5.